The number of patients living with obesity keeps growing, and following the recent advances in the therapeutic space, more ...

Vertex Pharmaceuticals expects another year of rapid growth in 2025, after achieving this in the fourth quarter and ...

Novartis today announced that it has entered into an agreement to acquire privately-held Anthos Therapeutics, which the Swiss ...

Shanghai-based biotech firm Hexaell Biotech has secured 200 million renminbi ($31 million) in a series B+ funding round. The ...

Caymen Islands-headquartered specialty drug firm Legacy Pharma has announced the completion of the acquisition of InterMune, ...

US pharma major Bristol Myers Squibb has announced that the Phase II TRANSCEND FL trial evaluating Breyanzi (lisocabtagene ...

French drugmaker Ipsen today released final results from the Phase III CheckMate -9ER trial of Cabometyx (cabozantinib) in ...

The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

The European Commission has launched a pilot program to simplify the approval process for certain clinical studies conducted ...

Q32 Bio (Nasdaq: QTTB) has announced a corporate restructuring, shifting its focus entirely to the development of its lead ...

South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.

Reacting to press reports, Germany’s Merck KGaA has confirmed it is in advanced discussions with SpringWorks Therapeutics with the aim of acquiring the US biotechnology company.